Skip to main content

SNP Applications Seen Saving Healthcare Industry $1 Billion by 2010

NEW YORK, March 12 – The ability to identify and assess SNPs will help to increase treatment efficacy and reduce adverse drug reactions, helping to save the healthcare industry more than $1 billion over the next decade, a survey released Monday by Front Line Strategic Management Consulting said.

The Foster City, Calif.-based consultancy said that treatment efficacy could increase by 32 percent over current levels while adverse drug reactions could be reduced by up to 25 percent.

In addition, Front Line estimated that cost savings from pharmacogenomics could rise to $33 million per drug by the year 2010.

“Driving the savings will be SNP genotyping, which will directly reduce clinical trial sample size and subsequently the overall length of clinical development,” Front Line said. “The SNP genotyping market will experience exponential growth through 2005 due to an increased number of compounds for which SNP genotyping will be utilized in clinical trials. The adoption of this technology will eventually drive growth to an expected peak in 2005 as it reaches over a billion dollars in value.” 

After studying a drug already on the market, Front Line estimated that revenues would have been $3.5 billion, or 45 percent, higher over the life of the drug had pharmacogenomics been applied to the drug’s development. 

“This 45% increase in revenues was obtained by decreasing the overall length of the drug discovery and development process. This would have allowed for earlier market introduction and thereby, extend the time for revenue growth,” Front Line said.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.